Evidence map›Paper›PMID 27536437›Full record

ArticleJournal of drug assessment2013

Effects of add-on montelukast on airway hyperresponsiveness in patients with well-controlled asthma - a pilot study.

Nina Kononowa, Sandra Michel, David Miedinger, Christiane E Pichler, Prashant N Chhajed, Arthur Helbling, Jörg D Leuppi

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug assessment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01725360 (Change of Airway Hyperresponsiveness to Mannitol and Methacholine During Intensified Anti-inflammatory Treatment in Patients With Asthma.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01725360 phase4completednot on this map

Change of Airway Hyperresponsiveness to Mannitol and Methacholine During Intensified Anti-inflammatory Treatment in Patients With Asthma.

TypeinterventionalSponsorCantonal Hospital, BasellandRan2007 to 2012Enrolled17ConditionsAsthmaArmsmontelukast
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nina KononowaClinic of Internal Medicine, University Hospital BaselSwitzerland.
Sandra MichelClinic of Allergology, University Hospital Basel, Switzerland; University Clinic of Rheumatology, Clinical Immunology and Allergology, University Hospital BernSwitzerland.
David MiedingerMedical Faculty, University of Basel and Clinic of Internal Medicine, Canton Hospital Baselland, LiestalSwitzerland.
Christiane E PichlerUniversity Clinic of Rheumatology, Clinical Immunology and Allergology, University Hospital BernSwitzerland.
Prashant N ChhajedMedical Faculty, University of Basel and Clinic of Internal Medicine, Canton Hospital Baselland, LiestalSwitzerland.
Arthur HelblingUniversity Clinic of Rheumatology, Clinical Immunology and Allergology, University Hospital BernSwitzerland.
Jörg D LeuppiMedical Faculty, University of Basel and Clinic of Internal Medicine, Canton Hospital Baselland, LiestalSwitzerland.
University of Basel · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveControl of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess the effects of a leukotriene receptor antagonist (LTRA) added to a basic treatment of inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) on airway hyperresponsiveness, inflammation, and quality of life in well-controlled patients with asthma. RESEARCH DESIGN AND

methodsSeventeen patients (age 18-65, 11 women) with well-controlled asthma presenting airway hyperresponsiveness to mannitol and methacholine challenge were given add-on montelukast on a stable ICS + LABA for 4 weeks. Quality of life and selected parameters of airway inflammation were measured at baseline and at study end. (ClinicalTrials.gov (NCT01725360)).

resultsAdding montelukast to ICS + LABA resulted in an increase in mean FEV1 (+4.5%, p = 0.057), cumulated higher dose of mannitol (+32.5%, p = 0.023) and methacholine (+17.2%, 0.237) in the provocation test, lower airway reactivity with mannitol and methacholine (response dose ratio (RDR) -50.0%, p = 0.024 and -44.3%, p = 0.006, respectively), and improved airway sensitivity to mannitol and methacholine (+12.1%, p = 0.590 and +48.0%, p = 0.129 for PD15 and PD20 FEV1, respectively). Changes in inflammation parameters (blood eosinophil count, serum eosinophil cationic protein, and exhaled nitric oxide) were consistent with these findings. Asthma-related quality of life improved significantly in all domains and overall (from 5.3 at baseline to 6.1 at the final visit, p < 0.001). The main limitation was the absence of a control group.

conclusionThe consistency of the changes in airway hyperresponsiveness and inflammation as well as in quality of life observed with an add-on therapy with montelukast in well-controlled asthma patients during 4 weeks suggests that residual inflammation may represent an area for further improvement of asthma control to be explored in adequately powered randomized controlled trials.

Indexed as

AHR, Airway hyperresponsiveness; AQLQ, Asthma Quality of Life Questionnaire; BHR, Bronchial hyperreactivity; BPT, Bronchial provocation test; ECP, Eosinophil cationic protein; FeNO, Fraction of exhaled nitric oxide; FEV1, Forced expiratory volume in one sAirway hyperresponsivenessAirway inflammationAsthmaAsthma controlLeukotriene receptor antagonistsMannitol provocation testMethacholine provocation test

Identifiers

PMID27536437
PMCPMC4937661
OpenAlexW1999944804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.